BCL2 and acute myeloid leukemia: Pan et al. (2017), using AML resistant mouse models, demonstrated that synthetic lethality induced by the combination of Bcl-2 inhibition (an anti-apoptotic protein) and p53 activation overcome apoptosis resistance in AML [263].